🔗 Share this article

Given that the US continues making unprecedented changes to its vaccination schedules, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about coronavirus vaccinations during the pandemic and has focused upon potential deaths after COVID-19 vaccination in her short position at the FDA.

Scheduled Overhauls to Pediatric Vaccine Schedule

Public health authorities planned to reveal major changes to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s vaccine program, it is understood – a significant shift that would put the US out of alignment with a large portion of the global community with insufficient data for benefit. The announcement has been delayed until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is listed to speak at the meeting. She was recently named temporary leader of the FDA’s CDER, the fifth person to lead the division this year.

A New Direction at the FDA

Høeg's temporary position might represent a closer partnership between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for ending specific childhood immunization guidelines in the US to become more similar to Denmark, a nation with universal health coverage and a number of inhabitants roughly the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on vaccination policy – usually the domain of Dr. Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Expertise

Høeg has little discernible background in drug development, approval processes or management, which has been typical for past leaders of the CBER. She has been employed at the FDA as a top consultant to the commissioner and CBER since March.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in managing a large organization. She is not an expert in drug approvals.”

Previous heads of the center would “understand legal statutes and the research of pharmaceutical innovation”, said Janet Woodcock. “Objectively, she lacks the type of experience that prior appointees who headed CBER have had.”

The drug center has an enormous range of responsibilities at the FDA, the former commissioner stated.

“Many people just zeroes in on the new drug program, but the off-patent medication office approves a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and more, and each of these need to be supervised,” she noted. “The thing you neglect, that’s the thing that I always told people is going to bite you.”

There is also, a major management element to the position, which manages in excess of 5,000 personnel. “It is a massive administrative position, if you perform it correctly,” she said.

Response and Contentious Policies

In response to inquiries about Dr. Høeg's fitness for the role and whether this selection represents more teamwork among FDA leaders on immunizations, a representative responded that the “inquiries stem from flawed presumptions”.

“This background matches the responsibilities of her job,” the representative said, citing the period Høeg spent advising the agency head on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a contentious one-day drug-approval program that allegedly worried her former heads. “How are these medications being picked for this expedited pathway? Who is making the calls?” Howard said. “There is a lot of confidentiality going on at the regulatory body right now.”

In general, he stated, “the agency looks to be trending towards laxer regulations of most medications, aside from shots.”

Established Past Work on Vaccines

With immunizations, Høeg has a more established, if troubling, past, some experts have noted. She authored a research paper using non-validated public submissions to estimate the frequency of myocarditis after COVID-19 vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccines are pose a greater threat than they are.

Among her “wish list” for the incoming government included changing rules for novel immunizations and ending “non-essential” immunizations, she said post-election on a online show. At the FDA, Høeg has allegedly suggested excluding adolescent males from receiving COVID-19 vaccines.

“She is an complete true believer who begins with her conclusions and works backwards to retrofit the evidence in a very deceptive, untruthful fashion,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined fellow skeptics, {like|